W. Simon
Bosch
25 Papers
184 Citations
W. Simon is an academic researcher from Bosch. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 12, co-authored 25 publications. Previous affiliations of W. Simon include Robert Bosch Hospital.
Chat about Author
Papers
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth,Matthew P. Goetz,Ute Hamann,Peter A. Fasching,Peter A. Fasching,Marcus Schmidt,Stefan Winter,Stefan Winter,Peter Fritz,Peter Fritz,W. Simon,Vera J. Suman,Matthew M. Ames,Stephanie L. Safgren,Mary J. Kuffel,Hans Ulrich Ulmer,Julia Boländer,Reiner Strick,Matthias W. Beckmann,Heinz Koelbl,Richard M. Weinshilboum,James N. Ingle,Michel Eichelbaum,Michel Eichelbaum,Matthias Schwab,Matthias Schwab,Hiltrud Brauch,Hiltrud Brauch +27 more
TL;DR: Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP 2D6 alleles was associated with better clinical outcomes and the absence of nonfunctional or reduced-function alleles with worse outcomes.
557
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Thomas E. Mürdter,Thomas E. Mürdter,Werner Schroth,Werner Schroth,L Bacchus‐Gerybadze,L Bacchus‐Gerybadze,L Bacchus‐Gerybadze,Stefan Winter,Stefan Winter,Georg Heinkele,Georg Heinkele,W. Simon,Peter A. Fasching,Tanja Fehm,Michel Eichelbaum,Michel Eichelbaum,Matthias Schwab,Matthias Schwab,Hiltrud Brauch,Hiltrud Brauch +19 more
TL;DR: Among the poor metabolizers, 93% had (Z)‐endoxifen levels below IC90 values, underscoring the role of CYP2D6 deficiency in compromised tamoxIFen bioactivation, and carriers of reduced‐function CYp2C9 (*2, *3) alleles had lower plasma concentrations of active metabolites (P < 0.004), pointing to the roleof additional pathways.
281
c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study
Peter Fritz,Cristina M. Cabrera,Jürgen Dippon,Andreas Gerteis,W. Simon,Walter E. Aulitzky,Heiko van der Kuip +6 more
TL;DR: The results of this exploratory study suggest that protein expression of c-erbB2 and topoisomerase IIα in primary breast cancer tissues are independent prognostic factors and are not exclusively predictive factors for anthracycline response in patients withPrimary breast cancer.
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast
Maike Sonnenberg,Heiko van der Kuip,Silke Haubeiß,Peter Fritz,Werner Schroth,Godehard Friedel,W. Simon,Thomas E. Mürdter,Walter E. Aulitzky +8 more
TL;DR: Similar to cancer cells, CAF response to chemotherapy is highly variable and the sensitivity of CAFs seems to depend also on the cancer type as well as the microenvironment.
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Matjaž Rokavec,Werner Schroth,Sandra Amaral,Peter Fritz,Lydia Antoniadou,Damjan Glavač,W. Simon,Matthias Schwab,Michel Eichelbaum,Hiltrud Brauch +9 more
TL;DR: Functional and patient-based results suggest that the TC21 -582C>T polymorphism improves prediction of tamoxifen treatment outcome in breast cancer.
34